Important Caveats About the Research Several important limitations should be acknowledged when reviewing the EpitalON literature: The majority of published studies originate from Khavinson's research group or closely affiliated laboratories Independent replication outside Russia has been limited, though the 2025 Biogerontology study represents a notable exception Human clinical data remains sparse, consisting mainly of small studies from one research group Most research has used injectable EpitalON, not oral formulations The peptide is not approved as a medicine in the UK, EU, or US How EpitalON Capsules Are Typically Taken Research Protocol Context The research literature commonly references cycles of 10-20 days at 5-10mg daily, repeated periodically (such as once or twice yearly)
L-ergothioneine and its combination with metformin attenuates renal dysfunction in type-2 diabetic rat model by activating Nrf2 antioxidant pathway
Bodily and visual-cognitive navigation aids to enhance spatial recall in mild cognitive impairment
As a medicine, it is used to treat burns, scratches, and wounds
Maibach (Eds.), Cosmeceuticals and Active Cosmetics: Drugs vs